Anne Wojcicki’s nonprofit reaches deal to accumulate 23andMe
Beleaguered genetic testing firm 23andMe introduced Friday that it has reached an settlement to promote itself to a nonprofit led by the corporate’s co-founder and former CEO Anne Wojcicki.
Following a large cyberattack in 2023 and a associated lawsuit settlement, 23andMe filed for chapter in March, with Wojcicki resigning so as to change into an impartial bidder for the corporate. However pharmaceutical firm Regeneron was introduced as the corporate’s acquirer with a $256 million bid.
In keeping with the Wall Road Journal, Wojcicki’s nonprofit TTAM Analysis Institute reopened the bidding course of by making an unsolicited bid earlier this month, and Regeneron declined to beat TTAM’s $305 million supply.
Within the announcement, TTAM (an acronym that corresponds with the primary letters of Twenty-Three And Me) stated that prospects might be notified of the acquisition at the least two enterprise offers earlier than the deal closes, and that the nonprofit will proceed to abide by 23andMe’s privateness insurance policies permitting prospects to delete their knowledge and opt-out of analysis. It additionally stated that it’ll set up a Client Privateness Advisory Board inside 90 days of closing.
“I’m thrilled that TTAM Analysis Institute will be capable to proceed the mission of 23andMe to assist individuals entry, perceive and profit from the human genome,” Wojcicki wrote on LinkedIn. “We consider it’s essential that people are empowered to have alternative and transparency with respect to their genetic knowledge and have the chance to proceed to study their ancestry and well being dangers as they need.”
The acquisition nonetheless must be accredited by the chapter courtroom, and it faces further authorized hurdles — a gaggle of 28 state attorneys common led by New York’s Letitia James filed a lawsuit this week objecting to the sale of the corporate’s property.
“23andMe can not public sale thousands and thousands of individuals’s private genetic info with out their consent,” James stated.
A court-appointed privateness ombudsman additionally stated it’s not clear that 23andMe’s privateness insurance policies permit for the sale of its genetic knowledge, in line with the WSJ.
Neither is it clear that 23andMe may regain client belief if the deal goes by means of. The corporate’s interim CEO Joseph Selsavage just lately instructed a Home Oversight Committee that 15% of consumers had requested to delete their knowledge for the reason that firm filed for chapter.